ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

BioNTech to buy cancer vaccine company Neon Therapeutics

by Ryan Cross
January 24, 2020 | APPEARED IN VOLUME 98, ISSUE 4

 

The German immuno-oncology company BioNTech will acquire Neon Therapeutics for a mere $67 million. Neon was founded in 2015 to develop personalized cancer vaccines that train a patient’s immune system to target tumor neoantigens. Neon raised $161 million from private investors before a $100 million initial public offering in June 2018. Since then, its clinical studies have failed to impress investors, and its stock has fallen 90%. In November 2019, the firm turned its focus to creating custom T-cell therapies with its neoantigen knowledge. That’s the program BioNTech is most excited about.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment